Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.

作者
Jean‐Pascal Machiels,Lisa Francesca Licitra,Yungan Tao,Chia‐Jui Yen,Danny Rischin,John N. Waldron,Barbara Ann Burtness,Vincent Grégoire,Sanjiv S. Agarwala,Jeffrey Thomas Yorio,Jean‐Pierre Delord,Sercan Aksoy,Sadakatsu Ikeda,Ruey‐Long Hong,Joy Yang Ge,Holly M. Brown,Behzad Bidadi,Lillian L. Siu
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:36 (15_suppl): TPS6094-TPS6094 被引量:6
标识
DOI:10.1200/jco.2018.36.15_suppl.tps6094
摘要

TPS6094 Background: Preclinical data in murine cancer models show improved tumor growth control and survival when radiation therapy (RT) is combined with a PD-1 inhibitor. Pembrolizumab is effective for treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), and initial results from a phase 1b study suggest that pembrolizumab plus chemoradiation therapy (CRT) is tolerable in patients with locally advanced (LA) HNSCC. KEYNOTE-412 (NCT03040999) is a phase 3, randomized, placebo-controlled, double-blind trial to determine efficacy and safety of pembrolizumab given with CRT and as maintenance therapy vs placebo plus CRT in LA-HNSCC. Methods: Patients will be randomly assigned (1:1) to receive pembrolizumab 200 mg every 3 weeks plus cisplatin-based CRT or placebo plus cisplatin-based CRT. Treatment will be stratified by RT regimen (accelerated RT [56-70 Gy, 6 fractions/week for 6 weeks] or standard RT [56-70 Gy, 5 fractions/week for 7 weeks]), tumor site/p16 status (oropharynx p16 positive vs p16 negative or larynx/hypopharynx/oral cavity), and disease stage (III vs IV). Priming dose of pembrolizumab or placebo will be given 1 week before CRT, followed by 2 doses during CRT, and an additional 14 doses after CRT, for a total of 17 pembrolizumab or placebo infusions. Eligibility criteria include age ≥18 years; newly diagnosed, treatment-naive, oropharyngeal p16–positive (any T4 or N3), oropharyngeal p16–negative (any T3-T4 or N2a-N3), or larynx/hypopharynx/oral cavity (any T3-T4 or N2a-N3) SCC; evaluable tumor burden (RECIST v1.1); and ECOG performance status 0-1. Treatment will be discontinued at the time of centrally confirmed disease progression, unacceptable toxicity, or patient/physician decision to withdraw. Patients will be evaluated to determine the necessity of neck dissection 12 weeks after completion of CRT. The primary end point is event-free survival. Secondary end points are overall survival, safety, and patient-reported outcomes. Relationship between biomarkers and clinical activity will be included as an exploratory end point. Recruitment is ongoing in 21 countries and will continue until ~780 patients are enrolled. Clinical trial information: NCT03040999.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小黑发布了新的文献求助10
刚刚
redamancy完成签到 ,获得积分10
刚刚
易128_完成签到,获得积分10
刚刚
h11的应助被T0Yu采纳,获得10
刚刚
刚刚
lry5211完成签到,获得积分10
刚刚
忧虑的汽车完成签到,获得积分10
1秒前
全能完成签到,获得积分10
1秒前
礼赞_完成签到,获得积分10
1秒前
1秒前
123完成签到,获得积分10
1秒前
cc完成签到,获得积分10
1秒前
1秒前
阳光的笑卉完成签到,获得积分10
2秒前
高分子聚合绿豆汤完成签到 ,获得积分10
2秒前
ll发布了新的文献求助40
2秒前
派大星完成签到,获得积分10
3秒前
3秒前
3秒前
天天开心完成签到,获得积分10
3秒前
缥缈芒果完成签到,获得积分10
5秒前
ZZD完成签到 ,获得积分10
5秒前
开心的老虎完成签到,获得积分10
5秒前
zjw发布了新的文献求助30
5秒前
灰灰完成签到,获得积分10
6秒前
kokok发布了新的文献求助20
6秒前
6秒前
敏感寒云完成签到,获得积分10
6秒前
JG发布了新的文献求助10
6秒前
ing完成签到 ,获得积分10
6秒前
青柳安发布了新的文献求助10
7秒前
ERIC完成签到,获得积分10
7秒前
Jenny完成签到,获得积分10
7秒前
溜溜完成签到,获得积分10
7秒前
wwww发布了新的文献求助10
7秒前
7秒前
7秒前
7秒前
自觉鸽子完成签到,获得积分10
8秒前
elsa完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159633
求助须知:如何正确求助?哪些是违规求助? 9555145
关于积分的说明 21725138
捐赠科研通 7749593
什么是DOI,文献DOI怎么找? 3427281
关于科研通互助平台的介绍 2552345
邀请新用户注册赠送积分活动 2471619